HighLife Medical Raises $90M Series C+ to Advance Transcatheter Mitral Valve Platform

HighLife Medical Closes $90M Series C+

HighLife Medical, a Paris-based medical device company developing transcatheter solutions for structural heart disease, has raised $90 million in Series C+ funding. The round was led by Supernova Invest.

What HighLife Medical Does

HighLife is focused on structural heart disease, with its efforts centered on a trans-septal transcatheter mitral valve replacement (TMVR) system. The system is designed for patients with moderate-to-severe or severe mitral regurgitation.

The company's approach uses a two-component valve-in-ring design, in which both the ring and the valve are implanted percutaneously. According to the company, this design mirrors the surgical gold standard of an annuloplasty ring plus a valve.

Founded in 2010, HighLife is headquartered in Paris and operates a US facility in Irvine, California. The company received CE Mark approval for both its TMVR system and the next-generation Clarity Valve in 2026.

The Round

• Round type: Series C+
• Amount: $90,000,000
• Currency: USD
• Date: September 22, 2026
• Lead investor: Supernova Invest

Participating Investors

• U.S. Venture Partners (USVP)
• European Investment Bank
• VI Partners
• Supernova Invest
• BNP Paribas Développement
• Critical Path Ventures
• Capricorn Partners
• Sofinnova Partners
• Andera Partners
• Sectoral Asset Management
• Merieux Equity Partners
• SPRIM Global Investments
• Pro Benefis Familiae

Why It Matters

The Series C+ extends HighLife's investor base across European and US venture, strategic, and institutional backers. The company's dual-market footprint — Paris headquarters and an Irvine, California facility — positions it within both the European and US medtech ecosystems.

With CE Mark approval already secured for its TMVR system and the next-generation Clarity Valve, HighLife enters this funding phase with regulatory milestones in hand for its core transcatheter mitral platform.

Acquisition Context

For acquirers and strategic partners in structural heart and transcatheter valve technologies, HighLife represents a clinically differentiated asset: a trans-septal TMVR system built on a two-component, valve-in-ring architecture that parallels established surgical practice. The company's CE Mark approvals for both its TMVR system and the Clarity Valve provide a regulatory foundation, while its transatlantic operational base offers access to both European and US markets.

The Series C+ brings together a broad syndicate including Supernova Invest as lead, alongside U.S. Venture Partners, the European Investment Bank, Sofinnova Partners, Andera Partners, and others — a mix of venture and institutional capital that reflects sustained interest in the transcatheter mitral space.

At a Glance

• Company: HighLife Medical
• Headquarters: Paris, France
• US Facility: Irvine, California
• Founded: 2010
• Focus: Transcatheter solutions for structural heart disease; trans-septal TMVR
• Regulatory: CE Mark for TMVR system and next-generation Clarity Valve (2026)
• Round: Series C+
• Amount: $90M
• Lead: Supernova Invest
• Date: September 22, 2026